Pharmacotherapeutic prophylaxis and post-operative outcomes within an Enhanced Recovery After Surgery (ERAS®) program: A randomized retrospective cohort study

Richard H Parrish 2nd, Rachelle Findley, Kevin M Elias, Brian Kramer, Eric G Johnson, Leah Gramlich, Gregg S Nelson, Richard H Parrish 2nd, Rachelle Findley, Kevin M Elias, Brian Kramer, Eric G Johnson, Leah Gramlich, Gregg S Nelson

Abstract

Background: Pharmacotherapy prophylaxis embedded in Enhanced Recovery After Surgery (ERAS®) protocols is largely unknown because data related to agent choice, dosing, timing, and duration of treatment currently are not collected in the ERAS Interactive Audit System (EIAS®). This exploratory retrospective randomized cohort study characterized pharmacologic regimens pertaining to prophylaxis of surgical site infections (SSI), venous thromboembolism (VTE), and post-operative nausea and vomiting (PONV).

Materials and methods: The records of 250 randomly-selected adult patients that underwent elective colorectal (CR) and gynecologic/oncology procedures (GO) at an ERAS® site in North America were abstracted using REDCap. In addition to descriptive statistics, bivariate associations between categorical variables were compared.

Results: Rates of SSI, VTE, & PONV were 3.3%, 1.1%, and 53.6%, respectively. Mean length of stay (LOS) for CR was 6.9 days and for GO, 3.5 days (p < 0.001). The most common antibiotic prophylaxis was one-time combination cefazolin 2 g and metronidazole 500 mg between 16 and 30 min preoperatively after chlorhexidine skin preparation. The most frequent VTE prophylaxis was tinzaparin 4500 units SC daily continued for at least 7 days after hospital discharge in oncology patients. PONV was related to longer LOS in both groups. Total morphine milligram equivalents (MME) was positively related to PONV and LOS in both CR & GO groups.

Conclusion: Guideline-consistent pharmacologic prophylaxis for SSI and VTE for both CR and GO patients was associated with low complication, LOS, and readmission rates. LOS in both groups was highly influenced by total MME, incidence of PONV and multi-modal anesthesia.

Keywords: Enhanced recovery after surgery; Infection; Length of stay; Nausea and vomiting; Postoperative; Surgical wound; Venous thromboembolism.

Conflict of interest statement

No conflicts to disclose.

© 2021 The Authors.

References

    1. Smith T.W.J., Wang X., Singer M.A., Godellas C.V., Vaince F.T. Enhanced recovery after surgery: a clinical review of implementation across multiple surgical subspecialties. Am. J. Surg. 2020;219:530–534.
    1. Arrick L., Mayson K., Hong T., Warnock G. Enhanced recovery after surgery in colorectal surgery: impact of protocol adherence on patient outcomes. J. Clin. Anesth. 2019;55(55):7–12.
    1. Currie A., Soop M., Demartines N., Fearon K., Kennedy R., Ljungqvist O. Enhanced Recovery after Surgery Interactive Audit System: 10 Years' experience with an international web-based clinical and research perioperative care database. Clin. Colon Rectal Surg. 2019;32:75–81.
    1. Ripollés-Melchor J., Ramírez-Rodríguez J.M., Casans-Francés R., Aldecoa C., Abad-Motos A., Logroño-Egea M., et al. Association between use of Enhanced Recovery after Surgery protocol and postoperative complications in colorectal surgery: the postoperative outcomes within Enhanced Recovery after Surgery protocol (POWER) Study. JAMA Surg. 2019;154:725–736.
    1. Pache B., Joliat G.-R., Hübner M., Grass F., Demartines N., Mathevet P., et al. Cost-analysis of enhanced recovery after surgery (ERAS) program in gynecologic surgery. Gynecol. Oncol. 2019;154:388–393.
    1. Wijk L., Udumyan R., Pache B., Altman A.D., Williams L.L., Elias K.M., et al. International validation of Enhanced Recovery after Surgery Society guidelines on enhanced recovery for gynecologic surgery. Am. J. Obstet. Gynecol. 2019;221:237. e1-237.e11.
    1. Elias K.M., Stone A.B., McGinigle K., Tankou J.I., Scott M.J., Fawcett W.J., et al. The reporting on ERAS compliance, outcomes, and elements research (RECOvER) checklist: a joint statement by the ERAS® and ERAS® USA Societies. World J. Surg. 2019;43:1–8.
    1. Nelson G., Bakkum-Gamez J., Kalogera E., Glaser G., Altman A., Meyer L.A., et al. Guidelines for perioperative care in gynecologic/oncology: enhanced Recovery after Surgery (ERAS) Society recommendations-2019 update. Int. J. Gynecol. Cancer. 2019;29:651–668.
    1. Weston E., Noel M., Douglas K., Terrones K., Grumbine F., Stone R., et al. The impact of an enhanced recovery after minimally invasive surgery program on opioid use in gynecologic oncology patients undergoing hysterectomy. Gynecol. Oncol. 2020;157:469–475.
    1. Peltrini R., Cantoni V., Green R., Greco P.A., Calabria M., Bucci L., et al. Efficacy of transversus abdominis plane (TAP) block in colorectal surgery: a systematic review and meta-analysis. Tech. Coloproctol. 2020;24:787–802.
    1. Resalt-Pereira M., Muñoz J.L., Miranda E., Cuquerella V., Pérez A. Goal-directed fluid therapy on laparoscopic colorectal surgery within enhanced recovery after surgery program. Rev. Esp. Anestesiol. Reanim. 2019;66:259–266.
    1. Liu Z., Dumville J.C., Norman G., Westby M.J., Blazeby J., McFarlane E., et al. Intraoperative interventions for preventing surgical site infection: an overview of Cochrane Reviews. Cochrane Database Syst. Rev. 2018;2:CD012653.
    1. Bisch S.P., Wells T., Gramlich L., Faris P., Wang X., Tran D.T., et al. Enhanced Recovery after Surgery (ERAS) in gynecologic oncology: system-wide implementation and audit leads to improved value and patient outcomes. Gynecol. Oncol. 2018;151:117–123.
    1. Hyde L.Z., Kiely J.M., Al-Mazrou A., Zhang H., Lee-Kong S., Kiran R.P. Alvimopan significantly reduces length of stay and costs following colorectal resection and ostomy reversal even within an enhanced recovery protocol. Dis. Colon Rectum. 2019;62:755–761.
    1. Hanna P., Kalapara A., Regmi S., Srujana K., Zabell J., Randle D., et al. Alvimopan as an essential component of ERAS protocol to decrease length of hospital stay. J. Clin. Oncol. 2020;38(6S):517.
    1. Hassinger T.E., Krebs E.D., Turrentine F.E., Thiele R.H., Sarosiek B.M., Hoang S.C., et al. Preoperative opioid use is associated with increased risk of postoperative complications within a colorectal-enhanced recovery protocol. Surg. Endosc. 2020;5:2067–2074.
    1. Mark J., Argentieri D.M., Gutierrez C.A., Morrell K., Eng K., Hutson A.D., et al. Ultrarestrictive opioid prescription protocol for pain management after gynecologic and abdominal surgery. JAMA Netw. Open. 2018;1
    1. Lovely J.K., Hyland S.J., Smith A.N., Nelson G., Ljungqvist O., Parrish R.H. Clinical pharmacist perspectives for optimizing pharmacotherapy within Enhanced Recovery after Surgery (ERAS®) programs. Int. J. Surg. 2019;63:58–62.
    1. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K., et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am. J. Health-sys. Pharm. 2013;70:195–283.
    1. Farge D., Bounameaux H., Brenner B., Cajfinger F., Debourdeau P., Khorana A.A., et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–e466.
    1. Hornor M.A., Duane T.M., Ehlers A.P., Jensen E.H., Brown P.S., Jr., Pohl D., et al. American college of surgeons' guidelines for the perioperative management of antithrombotic medication. J. Am. Coll. Surg. 2018;227:521–536.
    1. Apfel C.C., Heidrich F.M., ukar-Rao J.S., Jalota L., Hornuss C., Whelan R.P., et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br. J. Anaesth. 2012;109:742–753.
    1. Gan T.J., Belani K.G., Bergese S., Chung F., Diemunsch P., Habib A.S., et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth. Analg. 2020;131:411–448.
    1. Wan K.M., Carter J., Philp S. Predictors of early discharge after open gynecological surgery in the setting of an enhanced recovery after surgery protocol. J. Obstet. Gynaecol. Res. 2016;42:1369–1374.
    1. Lippitt M.H., Fader A.N., Wilbur M.B. Preventable surgical harm in gynecologic oncology: optimizing quality and patient safety. Curr. Obstet. Gynecol. Rep. 2017;6:298–309. doi: 10.1007/s13669-017-0226-y.
    1. Schwendimann R., Blatter C., Dhaini S., Simon M., Ausserhofer D. The occurrence, types, consequences and preventability of in-hospital adverse events - a scoping review. BMC Health Serv. Res. 2018;8:1–13.
    1. Thompson J.S., Baxter B.T., Allison J.G., Johnson F.E., Lee K.K., Park W.Y. Temporal patterns of postoperative complications. Arch. Surg. 2003;38:593–596.
    1. Blumetti J., Luu M., Sarosi G., Hartless K., McFarlin J., Parker B., et al. Surgical site infections after colorectal surgery: do risk factors vary depending on the type of infection considered? Surgery. 2007;142:704–711.
    1. El-Dhuwaib Y., Selvasekar C., Corless D.J., Deakin M., Slavin J.P. Venous thromboembolism following colorectal resection. Colorectal Dis. 2017;19:385–394.
    1. Fero K.E., Jalota L., Hornuss C., Apfel C.C. Pharmacologic management of postoperative nausea and vomiting. Expet Opin. Pharmacother. 2011;12:2283–2296.
    1. Franck M., Radtke F.M., Apfel C.C., Kuhly R., Baumeyer A., Brandt C., et al. Documentation of post-operative nausea and vomiting in routine clinical practice. J. Int. Med. Res. 2010;38:1034–1041.
    1. Sammour T., Chandra R., Moore J.W. Extended venous thromboembolism prophylaxis after colorectal cancer surgery: the current state of the evidence. J. Thromb. Thrombolysis. 2016;42:27–32. doi: 10.1007/s11239-015-1300-9.
    1. Rees P.A., Clouston H.W., Duff S., Kirwan C.C. Colorectal cancer and thrombosis. Int. J. Colorectal Dis. 2018;33:105–108.
    1. Johnson E., Parrish R., II, Nelson G., Elias K., Kramer B., Gaviola M. Expanding pharmacotherapy data collection, analysis, and implementation in ERAS® programs: the methodology of an exploratory feasibility study. Healthcare (Basel) 2020;8:252.
    1. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 2009;42:377–381.
    1. Agha R., Abdall-Razak A., Crossley E., Dowlut N., Iosifidis C., Mathew G., for the Strocss Group G. The STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int. J. Surg. 2019;72:156–165.
    1. Antor M.A., Uribe A.A., Erminy-Falcon N., Werner J.G., Candiotti K.A., Pergolizzi J.V., et al. The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting. Front. Pharmacol. 2014;5:55.
    1. Kim J.H., Lim M.-S., Choi J.W., Kim H., Kwon Y.S., Lee J.J. Comparison of the effects of sugammadex, neostigmine, and pyridostigmine on postoperative nausea and vomiting: a propensity matched study of five hospitals. J. Clin. Med. 2020;9:3477.
    1. Iniesta M.D., Lasala J., Mena G., Rodriguez-Restrepo A., Salvo G., Pitcher B., et al. Impact of compliance with an enhanced recovery after surgery pathway on patient outcomes in open gynecologic surgery. Int. J. Gynecol. Cancer. 2019;29:1417–1424.
    1. Nelson G., Wang X., Nelson A., Faris P., Lagendyk L., Wasylak T., et al. Evaluation of the implementation of multiple Enhanced Recovery after Surgery pathways across a provincial health care system in Alberta, Canada. JAMA Netw. Open. 2021;4
    1. Citty S.W., Bjarnadottir R.I., Marlowe B.L., Jones S., Lucero R.J., Garvan C.W., et al. Nutrition support therapies on the medication administration record: impacts on staff perception of nutrition care. Nutr. Clin. Pract. 2021;36:629–638.
    1. Gemma M., Pennoni F., Braga M. Studying enhanced recovery after surgery (ERAS®) core items in colorectal surgery: a causal model with latent variables. World J. Surg. 2021;45:928–939.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する